Pediatric attention deficit hyperactivity disorder (ADHD): 2022 updates on pharmacological management.

Lisa O'ConnorStephanie CarboneAnthony GobboHilary GambleStephen V Faraone

Published in: Expert review of clinical pharmacology (2023)

New formulations of medications include an evening administered, extended, and delayed-release form of methylphenidate (DR/ER MPH) a methylphenidate pro-drug (serdexmethylphenidate) and an amphetamine patch. The availability of a new SNRI (selective norepinephrine reuptake inhibitor), viloxazine-extended release (VER) and the pending approval of a triple reuptake inhibitor (centanafadine) provide welcome additions to the prescriber's toolbox.

Keyphrases

attention deficit hyperactivity disorder
autism spectrum disorder
working memory
emergency department
young adults
editorial comment
drug induced
childhood cancer